Sphenopalatine Ganglion Blocks RCT (SPGblock)
Primary Purpose
Migraine
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Lidocaine
Bupivacaine
Ropivacaine
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Migraine
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or more at time of consent
- Current patients in the UCSF Headache Center eligible to receive SPG blocks for migraine and would otherwise receive treatment clinically
- Ability to provide consent for the research study
Exclusion Criteria
- Pregnant or breast feeding within 4 weeks of enrollment
- Inability to communicate with the study team
- Patients who cannot read and understand English
- Deemed unsuitable for enrollment in study by the investigator
- Allergy to local anesthetics or saline
Sites / Locations
- UCSF Headache Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Lidocaine
Bupivacaine
Ropivacaine
Placebo (saline)
Arm Description
Participants will receive SPG blocks with lidocaine.
Participants will receive SPG blocks with bupivacaine
Participants will receive SPG blocks with ropivacaine
Participants will receive SPG blocks with placebo (saline)
Outcomes
Primary Outcome Measures
Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment
Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation
Secondary Outcome Measures
Full Information
NCT ID
NCT03666663
First Posted
September 8, 2018
Last Updated
September 14, 2021
Sponsor
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT03666663
Brief Title
Sphenopalatine Ganglion Blocks RCT
Acronym
SPGblock
Official Title
UCSF Sphenopalatine Ganglion Block Study- a Randomized Double Blind Placebo Controlled Trial to Compare Nasal Anesthetics for Migraine Prevention in Adults.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
February 1, 2019 (Actual)
Primary Completion Date
July 8, 2021 (Actual)
Study Completion Date
July 8, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.
Detailed Description
Chronic Migraine is a brain disorder with high prevalence. It is the 7th leading cause of disability worldwide according the WHO.
SPG block is a treatment for migraine that has been used for two decades. It can be done by needle injection of anesthetic to the region of the SPG. However, there are now multiple catheter devices that can be used to non-invasively administer anesthetic topically through the nasal cavity to the region of the SPG where the anesthetic is then absorbed through thin membranes covering the SPG.
Various anesthetic agents have been studied however currently, to our knowledge, there is no head to head comparison of the various anesthetics used. Studies of SPG blocks in the setting of chronic migraine are few as compared to the use of SPG as acute treatment for migraine.
With the use of an RCT, we aim to determine the overall efficacy of SPG blocks used at longer intervals than have been studied in the past as compared to placebo, as well as to examine the relative efficacy of the anesthetics used most commonly and studied for SPG blocks.
We will be using an FDA cleared device, the Sphenocath which was developed and registered with the FDA for this specific population and purpose. The study intervention is the standard practice in the UCSF Headache Center to perform SPG blocks for our patients with chronic migraine. The frequency we use in clinical practice and that we plan to study is less often than in previous studies of this intervention in this population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomized placebo controlled study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double blind study
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lidocaine
Arm Type
Experimental
Arm Description
Participants will receive SPG blocks with lidocaine.
Arm Title
Bupivacaine
Arm Type
Experimental
Arm Description
Participants will receive SPG blocks with bupivacaine
Arm Title
Ropivacaine
Arm Type
Experimental
Arm Description
Participants will receive SPG blocks with ropivacaine
Arm Title
Placebo (saline)
Arm Type
Placebo Comparator
Arm Description
Participants will receive SPG blocks with placebo (saline)
Intervention Type
Drug
Intervention Name(s)
Lidocaine
Intervention Description
Nasal application using the Sphenocath device- cleared by FDA
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
Nasal application using the Sphenocath device- cleared by FDA
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Intervention Description
Nasal application using the Sphenocath device- cleared by FDA
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo Saline
Intervention Description
Placebo Saline using the Sphenocath device- cleared by FDA
Primary Outcome Measure Information:
Title
Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment
Description
Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation
Time Frame
8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 years or more at time of consent
Current patients in the UCSF Headache Center eligible to receive SPG blocks for migraine and would otherwise receive treatment clinically
Ability to provide consent for the research study
Exclusion Criteria
Pregnant or breast feeding within 4 weeks of enrollment
Inability to communicate with the study team
Patients who cannot read and understand English
Deemed unsuitable for enrollment in study by the investigator
Allergy to local anesthetics or saline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nina Riggins, MD
Organizational Affiliation
UCSF Headache Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF Headache Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
1889975
Citation
Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 1991 Jun;31(6):365-71. doi: 10.1111/j.1526-4610.1991.hed3106365.x.
Results Reference
background
PubMed Identifier
21956040
Citation
Piagkou M, Demesticha T, Troupis T, Vlasis K, Skandalakis P, Makri A, Mazarakis A, Lappas D, Piagkos G, Johnson EO. The pterygopalatine ganglion and its role in various pain syndromes: from anatomy to clinical practice. Pain Pract. 2012 Jun;12(5):399-412. doi: 10.1111/j.1533-2500.2011.00507.x. Epub 2011 Sep 29. Erratum In: Pain Pract. 2012 Nov;12(8):673.
Results Reference
background
PubMed Identifier
26615983
Citation
Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L 4th, Kuruvilla D, Blumenfeld A, Berliner R, Rosen NL, Duarte R, Vidwan J, Halker RB, Gill N, Ashkenazi A. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. 2016 Feb;56(2):240-58. doi: 10.1111/head.12729. Epub 2015 Nov 30.
Results Reference
background
PubMed Identifier
30043973
Citation
Mehta D, Leary MC, Yacoub HA, El-Hunjul M, Kincaid H, Koss V, Wachter K, Malizia D, Glassman B, Castaldo JE. The Effect of Regional Anesthetic Sphenopalatine Ganglion Block on Self-Reported Pain in Patients With Status Migrainosus. Headache. 2019 Jan;59(1):69-76. doi: 10.1111/head.13390. Epub 2018 Jul 25.
Results Reference
background
PubMed Identifier
29862074
Citation
Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain Res Treat. 2018 May 7;2018:2516953. doi: 10.1155/2018/2516953. eCollection 2018.
Results Reference
background
PubMed Identifier
28432602
Citation
Mojica J, Mo B, Ng A. Sphenopalatine Ganglion Block in the Management of Chronic Headaches. Curr Pain Headache Rep. 2017 Jun;21(6):27. doi: 10.1007/s11916-017-0626-8. Erratum In: Curr Pain Headache Rep. 2017 Nov 20;21(12 ):53. Mojica, Jeffery [corrected to Mojica, Jeffrey].
Results Reference
background
Learn more about this trial
Sphenopalatine Ganglion Blocks RCT
We'll reach out to this number within 24 hrs